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Skin cancers are the most common form of cancer in humans. They can largely be categorized into
Melanoma and Non-melanoma skin cancers. The latter mainly includes Squamous Cell Carcinoma (SCC)
and Basal Cell Carcinoma (BCC), and have a higher incidence than melanomas. There has been a recent
emergence of interest in the role of non-coding RNA's in pathogenesis of skin cancers. The transcripts
which lack any protein coding capacity are called non-coding RNA. These non-coding RNA are further
classiﬁed based on their length; small non-coding RNA (<200 nucleotides) and long non-coding RNA
(>200 nucleotides). ncRNA They are involved at multiple transcriptional, post transcriptional and
epigenetic levels, modulating cell proliferation, angiogenesis, senescence and apoptosis. Their expression
pattern has also been linked to metastases, drug resistance and long term prognosis. They have both
diagnostic and prognostic signiﬁcance for skin cancers, and can also be a target for future therapies for
cutaneous malignancies. More research is needed to further utilize their potential as therapeutic targets.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Skin cancers are the most common form of cancer in humans.
They can largely be categorized intoMelanoma and Non-melanoma
skin cancers. The latter mainly includes Squamous Cell Carcinoma
(SCC) and Basal Cell Carcinoma (BCC), and have a higher incidence
than melanomas [1]. There has been a recent emergence of interest
in the role of non-codingRNA's (ncRNAs) in pathogenesis of skin
cancers. Majority of the studies focus on the role of ncRNA in epi-
genetics of melanoma and there is only limited amount of infor-
mation available on non-melanoma skin cancers. Herein, we
attempt to review the role of non-coding RNA in pathogenesis as
well as potential therapeutic targets for skin cancers.
Recent advances in sequencing technologies have questioned
the possible roles of entities that were previously considered to
have minimal or insigniﬁcant contribution in disease pathogenesis
and epigenetics. Although >75% of human genome is selectively
transcribed, only a small portion (1e2%) of transcripts are even-
tually translated into proteins. The transcripts which lack any
protein coding capacity are called non-coding RNA. These non-
coding RNA are further classiﬁed based on their length; smally, Icahn School of Medicine at
Y 10029, USA.
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(>200 nucleotides). Small non-codingRNA largely consists of
microRNA (<20 nucleotides) and small nucleolar RNA. MicroRNAs
are the most extensively studied group of RNAs which function in
negative regulation of gene expression by binding to target mRNA
leading to induction of degradation or inhibition of its translation.
Long non-coding RNAs also possess functional capacity owing to
their longer lengths and additional ability to fold upon themselves
forming tertiary structures [2,3].
The growing body of evidence suggests that ncRNA regulate key
tumor pathways and have shown to be involved in almost all hu-
man tumors. They are involved at multiple transcriptional, post
transcriptional and epigenetic levels, modulating cell proliferation,
angiogenesis, senescence and apoptosis (See Fig. 1). Their expres-
sion pattern has also been linked tometastases, drug resistance and
long term prognosis [4e9]. Resistance of cancers to chemothera-
peutic agents is the main clinical barrier to cure and improve
treatment outcomes. Therefore, better understanding of the role of
non-coding RNA will help us improve treatment and prognosis of
skin cancers.2. Role of ncRNA in skin cancers
Skin cancers are becoming a leading cause of morbidity and
mortality worldwide. Non-melanoma skin cancers are moreAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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Fig. 1. Role of ncRNAs in cancers.
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cancer related deaths. Early detection of melanoma is very impor-
tant in improving survival rates. Treatment options for advanced
melanoma are limited and needs more innovative strategies and
targets. Pathogenesis of melanoma is very complex and involves
interaction between a network of genes, regulatory mechanisms
and various signaling pathways. Non-codingRNAs have garnered
huge interest in the recent years regarding their role in tumori-
genesis, not limited to melanomas. Their potential role in patho-
genesis and as an early prognostic indicator needs further
elucidation.
Melanocytes are pigment producing cells that are derived from
neural crest cells. A series of steps ultimately lead to melanoblast
formation and transport as melanosomes to keratinocytes. A
number of melanocyte-speciﬁc proteins are expressed on mela-
nocytes such as: Tyrosinase, Tyrosinase Protein 1 and 2, Melano-
somal Matrix Protein and Microphthalmia Transcription Factor
(MITF) [10]. Other genes including MITF, SOX 10, PAX3, [11e13]
members of the Wnt and notch pathways [14e16], KIT and
cyclins [17] all play important roles in stepwise metamorphosis of
melanocytes. In addition to the contribution of protein coding
genes, many non-coding genes also have a vital contribution to the
signaling process. Small and long non-codingRNAs are discussed in
detail pertaining to their role in melanocyte biology and cancer
formation. Most commonly implicatedmiRNAs in skin cancers have
been described in Table 1.
2.1. MicroRNAs (miRNA) in melanocyte biology and immune
response
miRNAs are small noncoding RNA (<200 nucleotides) that are
involved in ﬁne tuning of more than 60% of proteins [18,19]. SeveralTable 1
List of non-coding RNAs currently implicated in skin cancers.
Non-coding RNA Target gene Type of non-coding RNA
miR-211 BRN2, KCNMA1, NFAT5, TGFBR2 microRNA
miR-200c ZEB1, DEF1, Nil-2-A microRNA
miR-210 PTPN1 TP53I11, HOXA1 microRNA
miR-196a HOX-B7, bFGF, BMP-4 microRNA
miR-30b GALNT7 microRNA
Let-7a Integrin beta 3 microRNA
SPRY4-IT1 n/a Antisense long non-coding
BANCR CXC11 Long intergenic noncoding
LlME23 PSF Long intergenic noncoding
ANRIL n/a Long intergenic noncoding
HOTAIR HOXC Long intergenic noncoding
miR-21 PTEN, BCL2 microRNA
miR-29c DNMT3A and DNMT3B microRNA
miR-124 ERK2 microRNA
miR-130a BCL-2 microRNA
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http://dx.doi.org/10.1016/j.ncrna.2016.11.003studies have conﬁrmed the aberrant expression of miRNAs in mel-
anoma cells speciﬁcallymiR-211. Several groups have demonstrated
thatmiR-211 as themost commonmiRNAexpresseddifferentially in
normal vs melanoma cells. Ectopic expression of miR-211 results in
inhibitionof growthand invasionofmelanomacells suggesting their
role as tumor suppressor gene [20,21]. This miR-211 is encoded by a
region in the sixth intron of TRPM1 (Transient Receptor Potential
cation channel subfamily Member M) [22]. The level of miR-211
expression in melanoma cells has been found to be inversely pro-
portional to the invasive potential ofmelanomasewithmelanomas
exhibiting reduced expression of miR-211 being highly invasive and
vice versa [20,21,23,24]. Bell et al. have identiﬁed a new miR-211
target, NUAK1 which promotes melanoma cell adhesion [23].
Another miRNA, namelymiR-196awas also shown to exhibit tumor
suppressor properties as its expressionwas signiﬁcantly reduced in
malignant melanoma cells [25] (see Fig. 1).
Conversely, overexpression of several miRNA's (miR-210, miR-
30b and miR-30) was seen to be upregulated in melanomas.
These miRNAs are linked to stimulation of an immunosuppressive
environment through cell-lysis by antigen-speciﬁc cytotoxic T
lymphocytes (CTLs), changes in glycosylating proteins and
increased synthesis of immunosuppressive molecules [26,27].
2.2. Role of miRNA in melanoma cell cycle and cell proliferation
Undifferentiated and uncontrolled cell proliferation is a hall-
mark of skin cancer. Cyclin dependent kinases and EF2 transcrip-
tion factors are the main cell cycle regulators. Other proteins such
as asc-myc, p27 and pTEN upregulate the CDKs and indirectly
function as cell cycle regulators. Non-coding RNAs particularly
miRNA directly targetthese cell cycle regulators [28e30]. let-7b is a
miRNA that decreases cell proliferation by targeting cell cycle
regulators by acting as a tumor suppressor gene [31]. Another
miRNA-193b downregulates cyclins D1 and D2 which are respon-
sible for uncontrolled cell growth and invasion [32]. Some miRNAs
are shown to indirectly control the cell cycle through p27 and p53
tumor suppressor genes. A few studies have shown that miR221/
222 directly inhibit p27and lead to increased proliferation of mel-
anoma cells. It has also been postulated that miR221/222 also
inhibit c-kit, PTEN and TIMP3 tumor suppressor genes [33,34].
Other miRNAs such as miR205, miR149, miR18b, miR21, miR203
and miR26a have been shown to regulate cell cycle proteins
through a cyclin independent manner [35].
2.3. Role of miRNA in tumor invasion
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met and NFK-b. Like other regulatory processes, miRNA have been
shown to actively regulate the above-mentioned proteins. In a
study by Segura et al., it was demonstrated that miR182 was
differentially expressed in melanoma vs benign melanocytes,
directly targeting proteins such as FOXO3 and MITF which
contribute to migration and invasion of melanoma cells. Animal
studies have demonstrated that miR182 can serve as a therapeutic
target as its expressionwas linked tometastasis of cancer in various
mouse models [36]. Another miRNA 145 is shown to downregulate
FSCN1 (fascin acting bundling protein 1) which is a known regu-
lator of cell migration and invasion [37,38].
2.4. Role of long ncRNA in melanoma
Long non-coding RNA are transcribed by RNA polymerase II as
an initial step which leads to formation of pri-ln cRNA. This is
subjected to further processing via splicing and polyadenylation
which ultimately results in formation of mature-lnc RNA. These
mature-lncRNAs possess an intrinsic ability to interact with RNA,
DNA and proteins as they can serve as tethers, decoys and scaffolds
owing to their tertiary structurewith surface interaction properties.
Thus, lncRNA play an important role in cell regulation, proliferation
and apoptosis [39e42]. Previously considered to be junk RNA, there
is growing evidence of their role in skin cancers. Unlike miRNA,
lncRNA has not been studied extensively and more research is
needed to elucidate their speciﬁc role in cancers.
2.5. Role of ncRNA in non-melanoma skin cancers
Early evidence suggests that microRNA also has a role in path-
ogenesis of non-melanoma skin cancers, including Basal Cell Car-
cinoma (BCC) and cutaneous squamous cell carcinoma (cSCC)e the
most common and the second most common forms of human
cancers respectively. The expression levels of miRNA machinery
(Drosha, DGCR8, AGO1, AGO2, PACT, and TARBP1) have been shown
to be signiﬁcantly higher in BCC and cSCC when compared to
healthy controls [43].
The role of long non-coding RNA has also been studied in several
cancers. Anticancer drug resistance has been shown to be associ-
ated with changes in expression of long non-coding RNA, sug-
gesting a novel pathway to identify and possible reverse tumor
drug resistance [44].
3. Conclusion
Skin cancers especially melanoma is resistant to many chemo-
therapeutic agents which is the main clinical barrier to improving
treatment outcomes and reducing melanoma related mortality.
With the increase in worldwide incidence of melanoma, it is
important to ﬁnd new and effective therapeutic targets. As
described in this article, non-coding RNAs play a very crucial role in
the pathology of skin cancers. They have both diagnostic and
prognostic signiﬁcance for skin cancers, and can also be a target for
future therapies for cutaneous malignancies. Early diagnosis of
melanoma remains the key to better treatment outcomes. There is
sufﬁcient evidence suggesting the key role of miRNA and lncRNA
was early diagnostic markers. More research is needed to further
utilize their potential as therapeutic targets.
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